Defining Venous Involvement in Borderline Resectable Pancreatic Cancer
Yun Shin Chun(The University of Texas MD Anderson Cancer Center), John P. Hoffman(Fox Chase Cancer Center), James C. Watson(University of Nebraska Medical Center), Barbara Burtness(Yale Cancer Center), Oleh Haluszka(Fox Chase Cancer Center), Igor Astsaturov(Fox Chase Cancer Center), Steven J. Cohen(Fox Chase Cancer Center), Jeffrey L. Tokar(Fox Chase Cancer Center), Barton N. Milestone(Fox Chase Cancer Center), Crystal S. Denlinger(Fox Chase Cancer Center), Paul F. Engstrom(Fox Chase Cancer Center), Michael J. Hall(Université Paris Cité)
Cited by 132
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
|Journal of Clinical Oncology|2000|746
Colon Cancer
|Journal of the National Comprehensive Cancer Network|2009|684
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|631